Spinal Muscular Atrophy Type 3 Clinical Trial
Official title:
A Multi-center, Open Label, Single-arm, Dose Ascending Clinical Trial for Evaluation of Safety and Efficacy of Gene Therapy Drug GC101 in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 3 (SMA 3) patients.
Status | Recruiting |
Enrollment | 21 |
Est. completion date | December 2028 |
Est. primary completion date | December 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years and older |
Eligibility | Inclusion Criteria: - =2 years of age on the day of signing the informed consent form; - Genetic and clinical diagnosis of type 3 SMA with bi-allelic deletion of SMN1 of 5qSMA; - Hammersmith Functional Motor Scale - Expanded (HFMSE) score is between 10 and 54 at screening; - Female patients of childbearing age who are pregnant or lactating, as well as all enrolled patients (both male and female), should take effective contraceptive measures within 6 months after the treatment; - Patients or patient's legal guardian(s) must be able to understand the purpose and risks of the study and voluntarily provide signed and dated informed consent prior to any study-related procedures being performed. Exclusion Criteria: - Patient who has participated in any previous gene therapy research trials; - Patient who has AAV9 neutralizing antibody titer =1:200; - Patient who has received Nusinersen within 120 days and Risdiplam within 15 days before treatment; - Patient who requires invasive or non-invasive ventilatory support averaging=16 hours/day at screening; - SMN2 copy numbers >4; - Patient who needs nasal or gastric tube feeding for eating; - Patient who is positive for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, hepatitis C antibody, or treponema pallidum antibody; - Known allergy or hypersensitivity to prednisolone or other glucocorticosteroids or their excipients - Severe contractures at screening that interfere with either the ability to attain/demonstrate functional measures or with the ability to receive intrathecal (IT) dosing; - Patient who has other serious diseases, such as severe cardiovascular and cerebrovascular diseases, digestive system diseases, urinary system diseases, endocrine system diseases, hematological diseases, immune system diseases, nervous system diseases (including but not limited to epilepsy, meningitis, history of convulsions or seizures, cerebrospinal fluid circulation disorders), and mental illnesses, etc.; - Patient with previous injuries (such as upper or lower limb fractures) or surgical operations that have not fully recovered or reached a stable state; - Vaccination no longer than 2 weeks before treatment; - Patient who has any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Tiantan Hospital, Capital Medical University | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
GeneCradle Inc |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | The proportion of patients whose Clinical Global Impression (CGI) is improved at Month 12 | 52 weeks | ||
Other | The proportion of patients whose Motor Function Measure (MFM) is improved or maintained at Month 12 | 52 weeks | ||
Other | Change from baseline of Forced Vital Capacity (FVC) at Month 12 ( for patients > 6 years) | 52 weeks | ||
Other | Change from baseline of Forced Expiratory Volume in 1 Second (FEV1) at Month 12 ( for patients > 6 years) | 52 weeks | ||
Other | Change from baseline of Maximal Inspiratory Pressure (MIP) at Month 12 ( for patients > 6 years) | 52 weeks | ||
Other | Change from baseline of Maximal Expiratory Pressure (MEP) at Month 12 ( for patients > 6 years) | 52 weeks | ||
Other | Change from baseline of 6 minutes walk test (6MWT) at Month 12 (for ambulatory patients) | The 6MWT is used for ambulatory participants with SMA and measures the total distance walked in 6 minutes. | 52 weeks | |
Other | Change from baseline of SMA Independence Scale (SMAIS) at Month 12 | The SMA Independence Scale (SMAIS) is a self-reported questionnaire to assess the amount of assistance patients require to perform daily activities. Higher SMAIS scores indicate greater independence.
(range: 0-44). |
52 weeks | |
Primary | Incidence of Treatment-Emergent Adverse Events | Frequency of treatment-related adverse events (AEs), serious adverse events (SAEs), and changes from baseline in relevant clinical laboratory tests | 52 weeks | |
Primary | Change from baseline on Hammersmith Functional Motor Scale - Expanded (HFMSE) scores at Month 12 | HFMSE consists of 33 activities that can be scored one of three ways: 0 for unable to perform, 1 for performs with modification/adaptation, and 2 for performs without modification. | 52 weeks | |
Secondary | The proportion of patients whose HFMSE improvement = 3 points at Month 12 | HFMSE =3 points:minimal clinically important differences (MCID) were considered for the outcomes: | 52 weeks | |
Secondary | Change from baseline on Revised Upper Limb Module (RULM) scores at Month 12 | RULM is a 20-item evaluation of upper limb function primarily used for those with SMA who are non-ambulatory (young children through adults). | 52 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06300996 -
Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb
|
N/A | |
Completed |
NCT04193085 -
Wearable Technology to Assess Gait Function in SMA and DMD
|
||
Completed |
NCT02895789 -
Oxidative Capacity and Exercise Tolerance in Ambulatory SMA
|
||
Terminated |
NCT03819660 -
Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3
|
Phase 2 | |
Recruiting |
NCT05272969 -
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
|
||
Recruiting |
NCT05544994 -
The Effect of Aerobic Exercise Training in Patients With Type III Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT02227823 -
Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3
|
Phase 2 | |
Active, not recruiting |
NCT05156320 -
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
|
Phase 3 | |
Recruiting |
NCT03709784 -
Spinraza in Adult Spinal Muscular Atrophy
|
||
Terminated |
NCT03056144 -
Whole Body Vibration Therapy in Children With Spinal Muscular Atrophy
|
N/A | |
Active, not recruiting |
NCT05430113 -
Spinal Cord Stimulation in Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT03921528 -
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
|
Phase 2 | |
Active, not recruiting |
NCT05626855 -
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab-ONYX
|
Phase 3 | |
Completed |
NCT04907162 -
Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders
|